Search Results 831-840 of 16993 for monoclonal antibody

1. Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE) - Mayo Clinic

   Monoclonal antibodies (anti-CD38 and anti-SLAMF7 antibody) within 4 weeks prior to leukapheresis;; Any other systemic therapy approved for the treatment of ...

2. Myelodysplastic Syndromes Clinical Trials - Mayo Clinic Research

   Monoclonal antibodies, such as nivolumab, may interfere with the ability of cancer cells to grow and spread. Midostaurin may stop the growth of cancer cells ...

3. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide - Mayo Clinic

   ... Antibody and Lenalidomide. Print details. Share; Facebook · Twitter. Overview; Participation eligibility; Participating Mayo Clinic info; More information ...

4. Discovery's Edge: Cell research on amyloidosis - Mayo Clinic News Network

   Antibodies are made up of two parts: “light chain” proteins in the two arms of the Y, and “heavy chain” proteins for the base of the Y. Antibody Protein ...

5. MS or not MS? Mayo Clinic Neuroimmunology Lab answers the question

   The AQP4 antibody, discovered at Mayo Clinic in 2004, was the first biomarker associated with inflammatory demyelinating diseases that could be used to ...

6. Cellular Therapy Clinical Trials - Mayo Clinic Research

   ... antibody (ANCA) associated vasculitis using primary samples and/or patient ... Monoclonal antibodies, such as pembrolizumab, may block tumor growth in ...

7. A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma - Mayo Clinic

   ... monoclonal antibody, daratumumab + bortezomib/thalidomide/dexamethasone \[D-VTd\] and daratumumab + bortezomib/ lenalidomide/dexamethasone \[D-VRd\]), or ...

8. A Trial of ZL-1201 in Subjects with Advanced Cancer - Mayo Clinic

   ... Antibody ZL-1201 in Subjects with Advanced Cancer. Participation eligibility ... Previous exposure to any anti-CD-47 monoclonal antibody or SIRPα antibody.

9. Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial - Mayo Clinic

   * Monoclonal gammopathy of undetermined significance ... * Known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies ...

10. A Phase 1/​2 Study of STP938 for Adult Subjects With Relapsed/​Refractory B-Cell and T-Cell Lymphomas - Mayo Clinic

    study drug. - Systemic cancer treatments, monoclonal antibody-directed therapies, other investigational agents within 4 weeks before enrollment, or <5 half ...